NEW YORK (GenomeWeb) – Cancer diagnostics firm Metamark Genetics has announced a coverage agreement with Anthem Blue Cross Blue Shield of Georgia.
Under the terms of the agreement, BCBS of Georgia will provide its members with in-network access to Metamark's suite of tests for urologic cancer.
Financial and other terms of the agreement were not disclosed.
"There is a growing recognition among payers nationwide of the benefits from our distinctive approach," Metamark CEO Jerry Williamson said in a statement.
The Georgia BCBS deal is the latest coverage and reimbursement victory for Cambridge, Massachusetts-based Metamark. Last month, Metamark announced that three Medicare contractors have issued draft local coverage determinations proposing reimbursement for the firm's proteomic ProMark prognostic test for early-stage prostate cancer.
The firm also has a coverage deal with Highmark Blue Shield. As of January, Metamark is the sole seller of the Hologic Progensa PCA3 prostate cancer test.